Markets6 August 2026
Hollywood's Most Profitable Hero
Sony brings the money, Marvel brings the vibes and Peter Parker gets caught in the middle of Hollywood's most profitable frenemy saga.
Manasvi Kommuri9 min read
Read ArticleArchive
All Articles
Browse market commentary, macro analysis, and student-led reporting.
The AI Infrastructure Arms Race: Tomorrow's Economy, or Yesterday's Bubble?
Big tech is on track to spend up to $690 billion on AI infrastructure this year alone. History suggests the technology can still win even as many of today's financiers lose everything.
Artificial IntelligenceBig TechCapital ExpenditureMarket Bubbles
Matthew Mahrous8 min read
Read ArticleMarkets3 August 2026
The Won's Great Reversal: How Chip Cash and a Rate Hike Rewired Korea's Currency
The won went from one of Asia's worst-performing currencies to one of the world's best in a matter of weeks, as chipmakers' overseas earnings came home, foreign equity selling eased, and the Bank of Korea ended a three-year rate freeze.
South KoreaCurrenciesBank of KoreaSemiconductorsMonetary Policy
Sonal Weerasekera8 min read
Read ArticleMarkets2 August 2026
Sainsbury's Recovered Most of Its Money on Argos. It Still Lost a Decade
Sainsbury's got most of its money back from Argos, and the integration did roughly what management said it would. The problem is what the capital earned in the meantime: Argos now makes a 0.2% margin.
Sainsbury'sArgosRetailPrivate Equity
Gaurav Bohra10 min read
Read ArticleMarketsGlobal Healthcare2 August 2026
The New Rules of Pharma M&A
Big Pharma is acquiring earlier and accepting greater scientific risk for unproven drugs. The driver is not confidence in the science but the fear of a rival securing the next blockbuster first, as a $300bn patent cliff bears down on the industry.
PharmaceuticalsMergers and AcquisitionsBiotechnologyPatent Cliff
Abdul Wasey Bhatti8 min read
Read ArticleMarkets2 August 2026
Why EQT Is Racing to Sell Private Equity to Individuals
The retail push looked like growth. It was really the industry building a capital base that does not depend on selling anything.
Private EquityEQTEvergreen FundsPrivate WealthLiquidityPrivate Credit
Abir Ghosh Biswas7 min read
Read ArticleMarkets24 July 2026
Eli Lilly's Fight Against Depression
After decades of underinvestment, scientific setbacks and fading industry interest, psychiatry is showing signs of life again. Eli Lilly's acquisition of AtaiBeckley, worth up to $3.8 billion, signals renewed hope that the future of depression treatment may look very different from the past.
Eli LillyPsychedelicsMental HealthBiotechMergers and Acquisitions
Abdul Wasey Bhatti6 min read
Read ArticleThe Concert Fee You Always Pay
A jury found Live Nation and Ticketmaster liable for illegal monopolisation in April 2026. The case is a study in how vertical integration converts dominance in one business into control over an entire industry.
Live NationTicketmasterAntitrustMonopolyLive Events
Jay Patel8 min read
Read ArticleThe Fed's Hawkish Turn: Why Kevin Warsh Is Flirting With a Rate Hike as Inflation Proves Sticky
New Fed chair Kevin Warsh was expected to bring a dovish, rate-cutting sensibility to the central bank. Instead, his first meeting delivered the most hawkish surprise markets have seen in years, with traders now pricing in the Fed's first hike since 2023.
Federal ReserveInflationMonetary PolicyKevin WarshInterest Rates
Sonal Weerasekera7 min read
Read ArticleThe NATO Paradox: Autonomy Off the Shelf
With the old black box monopolies breaking apart, private capital has emerged to underwrite the next era of European warfare.
Manasvi Kommuri8 min read
Read ArticleMarketsGlobal Healthcare16 July 2026
AstraZeneca's Bet on the Future of COPD Treatment
A $200 million upfront payment, with milestones potentially taking the deal's total value to $1.9 billion, gives AstraZeneca exclusive rights to develop and commercialise an experimental COPD treatment outside China. More importantly, it highlights a broader shift in how Big Pharma is sourcing innovation.
AstraZenecaPharmaceuticalsBiotechChinaCOPD
Abdul Wasey Bhatti4 min read
Read ArticleThe Concentration Trap: Why Private Equity's Revival Is Leaving Most of the Industry Behind
Global PE fundraising is rising but the number of funds closing is collapsing. The industry is not recovering. It is concentrating, and the zombie firm data suggests the structural shift is already irreversible for much of the market.
Private EquityFundraisingZombie FirmsIPOPublic Markets
Alexander Eklund7 min read
Read Article